US20110152544A1 - Process for the preparation 2-substituted derivatives of estrone and estradiol - Google Patents

Process for the preparation 2-substituted derivatives of estrone and estradiol Download PDF

Info

Publication number
US20110152544A1
US20110152544A1 US13/031,975 US201113031975A US2011152544A1 US 20110152544 A1 US20110152544 A1 US 20110152544A1 US 201113031975 A US201113031975 A US 201113031975A US 2011152544 A1 US2011152544 A1 US 2011152544A1
Authority
US
United States
Prior art keywords
compound
general formula
group
alkyl
atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/031,975
Inventor
Johannes Stoelwinder
Nicolaas Elisabeth Cornelis Moers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon NV
Original Assignee
Organon NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon NV filed Critical Organon NV
Priority to US13/031,975 priority Critical patent/US20110152544A1/en
Publication of US20110152544A1 publication Critical patent/US20110152544A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J75/00Processes for the preparation of steroids in general
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J75/00Processes for the preparation of steroids in general
    • C07J75/005Preparation of steroids by cyclization of non-steroid compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • This invention relates to a process for the preparation of 2-substituted-derivates of estrone and estradiol.
  • 2-methoxyestradiol, 1,3,5(10)-estratrien-2,3,17b-triol-2-methyl-ether (2-ME2) is an endogenous metabolite of estradiol.
  • 2-ME2 has low estrogenic activity, but has been found to have important other biological effects, such as anti-cancer activity, as described herein below.
  • U.S. Pat. Nos. 5,504,074, 5,66,143 and 5,892,069 describe methods of treating mammalian diseases characterized by abnormal cell mitosis using 2-ME2.
  • WO-A-02/42319 describes 2-ME2 for the treatment of disease states characterized by abnormal angiogenesis.
  • Undesirable cell mitosis is characteristic of many diseases, including, but not limited to, cancer, atherosclerosis, proliferation of solid tumors, vascular malfunctions, endometriosis, retinopathies, arthropathies, and abnormal wound healing.
  • cell mitosis is important in a wide variety of biological functions, including but not limited to the normal development of the embryo, formation of the corpus luteum, cyclic proliferation of uterine endometrium, wound healing and inflammatory and immune responses.
  • 2-ME2 Any therapeutic use of 2-ME2 in humans requires 2-ME2 having a high level of purity.
  • 2-ME2 since 2-ME2 has effects that are counteracted by estradiol and other estrogenic metabolites, it is desirable to have a 2-ME2 preparation substantially free of such contaminants.
  • Effects that may be seen from contaminating estradiol, estrone and 2-hydroxtyestradiol include estrogenic effects such as feminization, endometrial proliferation, increased risk of uterine and breast cancer, developmental effects on sexual organs, inhibition of leucopoiesis and effects on haematopoietic cells.
  • 4-hydroxyestradiol, 4-methoxyestradiol and estradiol are known to be at least suspected carcinogens.
  • EP-A-0776904 relates to the completely different technical field of the preparation of alkylketals of 3-keto-5(10),9(11)-gonadiene-derivatives. In its examples the preparation of such a gonadiene-derivative starting from estra-4,9-diene-3,17-dione is described.
  • the estra-4,9-diene-3,17-dione compound is prepared by condensing (+)5 ⁇ -hydroxy-7a ⁇ -methyl-2,3,3a ⁇ ,4,5,6,7,7a-octahydro-1H-inden-1-one-4 ⁇ -(3-propionic acid)-lacton with 2-pentanone-neopentylacetale-5-magnesium chloride; oxidizing the 5 ⁇ -hydroxy group; ring closure of the first ring (B); ketal cleavage; and ring closure of the second ring (A).
  • EP-A-0776904 does not describe nor suggest the preparation of 2-substituted derivatives of estra-4,9-diene-3,17-dione.
  • FIG. 1 Reaction scheme for the preparation of 2-(3-chloro-1-methoxy-propyl)-2,5,5,-trimethyl-[1,3]dioxane.
  • FIG. 2 Reaction scheme for the preparation of 2-methoxy-estradiol.
  • the newly found route can start from sitolactone or a derivative thereof.
  • Sitolactone is relatively inexpensive making such a route economically more attractive than for example the route described by J. Fishman.
  • this invention provides a process for the preparation of 2-substituted-derivatives of estrone and estradiol comprising
  • R1 is a C1-C10 alkyl, alkenyl or aryl group; —Cl, —Br, —I, —F; —CN; —OH; or a —OR2, —O(CO)R2 or —R2-OH group, wherein R2 is an alkyl or alkylene group having 1-6 C atoms; and the bonding between atoms 9 and 10 is a single or a double bond.
  • R1 and R2 have the above defined meanings.
  • this invention provides several novel compounds, which can be intermediates in the above process, and processes to prepare these novel compounds.
  • the process of the invention can be used to prepare 2-alkoxy-estrone or 2-alkoxy-estradiol, or mixtures thereof, containing essentially no estrogenic intermediates.
  • this invention provides a process for the preparation of estrone, estrone-derivates, estradiol and/or estradiol-derivates.
  • the process is, however, especially advantageous for the preparation of 2-alkoxy derivatives of estrone and/or estradiol.
  • the present invention provides a process as described above for the preparation of 2-alkoxy derivatives of estrone and/or estradiol, i.e. estrone and/or estradiol substituted at position 2 with an alkoxy group.
  • the present invention provides such a process for the preparation of 2-methoxy-estrone and/or 2-methoxy-estradiol. As explained above such a process is especially advantageous because of the minimization of any estrogenic intermediates in the final product.
  • R1 in formulae II, III and IV can be a branched or straight alkyl group having from 1 to 10 carbon atoms, such as for example methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert.-butyl, pentyl, isopentyl, tert.-pentyl or neo-pentyl, hexyl, heptyl, octyl, nonyl or decyl.
  • R1 is an alkyl group
  • R1 is a methyl or ethyl group.
  • R1 is an alkenyl group
  • R1 is an alkenyl group
  • R1 iso-propenyl
  • R1 is an aryl group
  • R1 is an alkenyl group
  • R1 in formula II, III and IV is —OH; or an —OR2 group, wherein R2 is an alkyl group having 1 to 6 carbon atoms.
  • R1 is an C1-C6-alkoxy group, i.e. an —OR2 group, wherein R2 is a straight or branched alkyl group having 1 to 6 carbon atoms. Examples of such alkoxy groups include methoxy-, ethoxy-, propoxy-, isopropoxy-, butyloxy-, pentyloxy, hexyloxy-.
  • R1 in formulae II, III and IV is a methoxy or ethoxy group, and in a still further embodiment R1 is a methoxy group.
  • the invention provides a process for the preparation of 2-alkoxy estrone and/or 2-alkoxy-estradiol.
  • 2-alkoxy-estrone prepared according to step ii) of the process, 2-alkoxy-estradiol can be obtained.
  • the bonding between atoms 9 and 10 in formula II can be a single or a double bond. In a specific embodiment of this invention, however, the bonding between atoms 9 and 10 is a double bond.
  • step ii) of the compound of general formula II to the compound of general formula III can be carried out in any manner known to the skilled person to be suitable for the process.
  • aromatization methods include the use of an aromatization agent such as potassium tert-pentoxide, and acetic anhydride; and the use of enzymes such as aromatase.
  • the aromatization is carried out by potassium pentoxide.
  • the aromatization is carried out by using lithium in ethylene diamine.
  • the aromatization can result in two isomers of the compound of general formula III, a 9-alfa-H- and a 9-beta-H-isomer. Of these, preparation of the naturally in the human body existing 9-alfa-H isomer is preferred.
  • Advantageously aromatization of a compound of general formula II, wherein the bonding between atoms 9 and 10 is a double bond, with lithium in ethylene diamine results in a mixture of isomers comprising a majority of the 9-alfa-H isomer.
  • reaction is carried out in a suitable solvent.
  • suitable solvents include diethyl amine, tetrahydrofuran; and mixtures thereof.
  • the temperature during the reaction can vary widely. In one embodiment the reaction is carried out at a temperature in the range from 0° to 60° C. In a specific embodiment the reaction is carried out at room temperature (20-25° C.).
  • the mixture is subsequently quenched with a basic solution to remove residual starting material from the mixture via an acid-base extraction.
  • the reduction in step iii) of the compound of general formula III to the compound of general formula IV can be carried out in any manner known by the skilled person to be suitable for this purpose.
  • the reduction is carried out with the help of a reduction agent.
  • suitable reduction agents include NaBH 4 and LiAlH 4 .
  • NaBH 4 is used as a reduction agent.
  • the reaction is carried out in a suitable solvent.
  • suitable solvents include alkanols such as methanol and ethanol; diethyl amine; tetrahydrofuran; and mixtures thereof.
  • the temperature during the reaction can vary widely. In one embodiment the reaction is carried out at a temperature in the range from 0° to 70° C. In a specific embodiment the reaction is carried out at room temperature (20-25° C.)
  • R1 and R2 are as specified herein above; and the bonding between atoms 9 and 10 is a single or a double bond.
  • R1 is a C1-C6-alkoxy group, i.e. an —OR2 group, wherein R2 is a straight or branched alkyl group having 1 to 6 carbon atoms.
  • alkoxy groups include methoxy-, ethoxy-, propoxy-, isopropoxy-, butyloxy-, pentyloxy, hexyloxy-.
  • R1 in formulae II, III and IV is a methoxy or ethoxy group, and in a further embodiment R1 is a methoxy group.
  • the compound of general formula II is prepared from a compound with formula I, also called sitolactone((4aS-(4a ⁇ ,6a ⁇ ,9a ⁇ ,9b ⁇ ))-decahydro-6a-methylcyclo-penta(f)(l)benzopyran-3,7-dione).
  • R1 and R2 have the above defined meanings;
  • R3 and R4 independently are an alkyl group comprising 1 to 6 carbon atoms; and
  • X is chosen from Cl or Br;
  • R1, R2, R3 and R4, have the above defined meanings
  • R1, R2, R3 and R4, have the above defined meanings
  • R1, R2, R3 and R4, have the above defined meanings
  • step a) the coupling reaction in step a) is carried out with help of a Grignard reaction, wherein the compound of general formula V is first converted into a compound of general formula Va.
  • Suitable solvents for this reaction include diethyl ether, tetrahydrofuran and mixtures thereof.
  • powdered magnesium is used, which is activated with dibromoethane, whereafter the compound of general formula V is added to prepare the compound of general formula Va.
  • the latter is added portion wise into a solution or suspension comprising the compound of general formula I to generate a compound of general formula VI.
  • the reaction is carried out at refluxing temperature and at atmospheric pressure (1 bar).
  • the obtained product is purified by crystallisation from a 1:1 mixture of heptane and ethyl acetate.
  • the oxidation of the hydroxy group of the compound of general formula VI to generate a compound of general formula VII in step b) can be carried out by any oxidation method known by the skilled person to be suitable for this purpose.
  • suitable oxidation methods include the treatment with an oxidation agent such as chromic acid, chromium oxide/pyridine, chlorine/pyridine, calcium dichromate, pyridine chromates and N-bromosuccinimide; and the Oppenauer oxidation.
  • the oxidation is carried out by oxidation with chromic acid in acetone.
  • the oxidation is carried out with tetra-n-propyl ammonium perruthenate (TPAP) and N-methylmorpholine N-oxide (NMO).
  • TPAP tetra-n-propyl ammonium perruthenate
  • NMO N-methylmorpholine N-oxide
  • dichloromethane can be used.
  • the ring-closing of the B-ring of the compound of general formula VII to prepare a compound with general formula VIII in step c) can be carried out in any manner known by the skilled person to be suitable for this purpose.
  • the B-ring is understood those carbon atoms that form the B-ring in the final product estrone- or estradiol derivate.
  • the ring-closing step is carried out by an aldol condensation under alkaline conditions, which condensation is in a further embodiment followed by a dehydration of the aldol product.
  • suitable bases include potassium-tert-butoxide, potassium-tert-pentoxide, sodium hydroxide, potassium hydroxide. The skilled person will further recognize that many more bases can be used.
  • the reaction is carried out in a suitable solvent.
  • suitable solvents include toluene; alkanols such as methanol, ethanol and isopropanol; tetrahydrofuran; and mixtures thereof.
  • a mixture of methanol, toluene and water is used as a solvent.
  • the temperature during the reaction can vary widely. In one embodiment the reaction is carried out at a temperature in the range from 0° to 80° C. In a specific embodiment the reaction is carried out at room temperature (20°-25° C.). In another specific embodiment the reaction is carried out at a temperature in the range from 55° to 75° C.
  • the obtained compound of general formula VIII is purified by crystallisation from a suitable solvent such as an alcohol. In a specific embodiment the compound of general formula VIII is purified by crystallisation in isopropanol.
  • step d) The preparation of a compound of general formula II from the compound of general formula VIII according to step d) can be carried out by any manner known by the skilled person to be suitable for this purpose.
  • the reaction of step d) comprises
  • R1 and R2 have the above defined meanings
  • reaction of step d) comprises
  • A-ring By the A-ring is understood those carbon atoms that form the A-ring in the final product estrone- or estradiol derivate.
  • the hydrolysis of step d1) can be carried out in any manner known by the skilled person to be suitable for this purpose.
  • the hydrolysis is carried out under acidic conditions.
  • suitable hydrolysis agents include hydrohalogens, phosphoric acids, sulfonic and sulfuric acids, such as hydrochloric acid, sulfuric acid, para-toluene sulfonic acid and phosphoric acid.
  • sulfuric acid H 2 SO 4
  • Any solvent known by the skilled person to be suitable for this purpose can be used as solvent during the reaction.
  • suitable solvents include C1-C6 alkanols, such as methanol, ethanol, propanol and isopropanol.
  • ethanol is used as a solvent.
  • the temperature during the reaction can vary widely. In one embodiment the reaction is carried out at a temperature in the range from 0° to 40° C., and in a specific embodiment the reaction is carried out at room temperature (20°-25° C.).
  • the ring-closure of the A-ring of step d2) can be carried out in any manner known by the skilled person to be suitable for this purpose.
  • the ring-closing step is carried out by an aldol condensation under alkaline conditions, which condensation is in a further embodiment followed by a dehydration of the aldol product.
  • suitable bases include potassium-tert-butoxide, potassium-tert-pentoxide, sodium hydroxide, potassium hydroxide.
  • the skilled person will further recognize that many more bases can be used.
  • the reaction is carried out in a suitable solvent.
  • Suitable solvents include toluene; alkanols such as methanol, ethanol and isopropanol; tetrahydrofuran; and mixtures thereof.
  • the temperature during the reaction can vary widely. In one embodiment the reaction is carried out at a temperature in the range from 0° to 80° C. In a specific embodiment the reaction is carried out at room temperature (20°-25° C.).
  • the hydrogenation of step d3) can be carried out in any manner known by the skilled person to be suitable for this purpose.
  • Pd/C and hydrogen are used for the hydrogenation.
  • the reaction is carried out in a suitable solvent.
  • suitable solvents include tetrahydrofuran; alkanols such as methanol, ethanol and isopropanol; and mixtures thereof.
  • ethanol is used as a solvent.
  • the temperature during the reaction can vary widely. In one embodiment the reaction is carried out at a temperature in the range from 0° to 80° C. In a specific embodiment the reaction is carried out at a temperature in the range from 25° to 60° C.
  • the hydrolysis of step d4) can be carried out in any manner known by the skilled person to be suitable for this purpose.
  • the hydrolysis is carried out under acidic conditions.
  • suitable hydrolysis agents include hydrohalogens, phosphoric acids, sulfonic and sulfuric acids, such as hydrochloric acid, sulfuric acid, para-toluene sulfonic acid and phosphoric acid.
  • sulfuric acid H 2 SO 4
  • Any solvent known by the skilled person to be suitable for this purpose can be used as solvent during the reaction.
  • suitable solvents include C1-C6 alkanols, such as methanol, ethanol, propanol and isopropanol.
  • ethanol is used as a solvent.
  • the temperature during the reaction can vary widely. In one embodiment the reaction is carried out at a temperature in the range from 0° to 40° C., and in a specific embodiment the reaction is carried out at room temperature (20°-25° C.).
  • the ring-closure of the A-ring of step d5) can be carried out in any manner known by the skilled person to be suitable for this purpose.
  • the ring-closing step is carried out by an aldol condensation under alkaline conditions, which condensation is in a further embodiment followed by a dehydration of the aldol product.
  • suitable bases include potassium-tert-butoxide, potassium-tert-pentoxide, sodium hydroxide, potassium hydroxide.
  • the skilled person will further recognize that many more bases can be used.
  • the reaction is carried out in a suitable solvent.
  • Suitable solvents include toluene; alkanols such as methanol, ethanol and isopropanol; tetrahydrofuran; and mixtures thereof.
  • the temperature during the reaction can vary widely. In one embodiment the reaction is carried out at a temperature in the range from 0° to 80° C. In a specific embodiment the reaction is carried out at room temperature (20°-25° C.).
  • R1, R2, R3 and R4 have the above defined meanings; and X is chosen from Cl or Br.
  • R3 and R4 are independently methyl or ethyl groups.
  • R3 and R4 are methyl groups and R1 is a methoxy group.
  • suitable compounds according to general formula V include for example 2-(3-chloro-1-methoxy-propyl)-2,5,5-trimethyl-[1,3]dioxane and 2-(3-bromo-1-methoxy-propyl)-2,5,5-trimethyl-[1,3]dioxane.
  • Examples of suitable compounds according to general formula Va include for example 3-methoxy-2-pentanone-neopentylacetale-5-magnesium chloride and 3-methoxy-2-pentanone-neopentylacetale-5-magnesium bromide.
  • the compounds of general formula (V) can for example be prepared by halogenation of a suitably substituted propene compound; substitution of one halogen atom by a nitrile group; addition of a methyl group by a grignard reaction and conversion into the 5-chloro-pentan-2-one compound substituted at its 3 position by an appropriate group; and reaction with neopentylglycol under acidic conditions to obtain the compound of general formula (V).
  • the preparation of 2-(3-chloro-1-methoxy-propyl)-2,5,5-trimethyl-[1,3]dioxane is illustrated in FIG. 1 .
  • R1, R2, R3 and R4 have the above defined meanings.
  • R1, R2, R3 and R4 have the above defined meanings.
  • R1, R2, R3 and R4 have the above defined meanings.
  • R1 and R2 have the above defined meanings.
  • R1, R2, R3 and R4 are as defined above.
  • R1 and R2 are as defined above.
  • the invention is illustrated by the following non-limiting examples and the reaction scheme in FIG. 2 .
  • Step A Preparation of (3a ⁇ ,4 ⁇ ,5 ⁇ ,7a ⁇ )-5-hydroxy-7a-methyl-4[7-(2,5,5-trimethyl-1,3-dioxan-2-yl)-5-methoxy-3-oxohexyl]-1H-inden-1-one
  • Magnesium powder 50 Mesh (10 g) was suspended in dry tetrahydrofuran (70 ml). The suspension was heated up to 50° C. After adding dibromoethane (500 ⁇ l), a vigorous reaction occurred. An initial portion of 2-(3-chloro-1-methoxy-propyl)-2,5,5-trimethyl-[1,3]dioxane (2 g) was added. After 1 h stirring at reflux 2-(3-chloro-1-methoxy-propyl)-2,5,5-trimethyl-[1,3]dioxane (35 g) was added. After stirring at reflux for 20 h the reaction mixture was cooled to 20° C.
  • the suspension was stirred for 1 h and filtered over a Dicalite® filter.
  • the filter was washed with dichloromethane (2 ⁇ 100 ml).
  • Step B Preparation of (3a ⁇ ,4 ⁇ ,5 ⁇ ,7a ⁇ )-5-oxo-7a-methyl-4[6-(2,5,5-trimethyl-1,3-dioxan-2-yl)-5-methoxy-3-oxohexyl]-1H-inden-1-one, oxidation of the hydroxy group
  • Step C Preparation of (3a ⁇ ,9a ⁇ ,9b ⁇ )-4,5,8,9,9a,9b-hexahydro-3a-methyl-6-(2-(2,5,5-trimethyl-1,3-dioxan-2-yl)-1-methoxy-ethyl)-1H-benz(e)indene-3,7(2H,3aH)-dione, formation of the B-ring
  • Potassium tert-butoxide (6.4 g) was suspended in toluene (100 ml) and 2-propanol (32 ml) at 20° C.
  • reaction mixture was acidified with acetic acid (8 ml) to pH 4.
  • the water layer was extracted with toluene (3 ⁇ 100 ml) and the combined organic layer was extracted with a solution of sodium hydroxide (5 g) in water (100 ml). The organic layer was evaporated to dryness in vacuo at 50° C.
  • the solution was stirred at 70° C. for 30 min and then cooled to 20° C.
  • Step B and C Preparation of (3a ⁇ ,9a ⁇ ,9b ⁇ )-4,5,8,9,9a,9b-hexahydro-3a-methyl-6-(2-(2,5,5-trimethyl-1,3-dioxan-2-yl)-1-methoxy-ethyl)-1H-benz(e)indene-3,7(2H,3aH)-dione; Combined oxidation and aldol condensation
  • reaction mixture After stirring the reaction mixture at ⁇ 2° C. for 2 h, the reaction mixture was poured into a solution of sodium sulfite (93 g) and sodium carbonate (78 g) in water (750 ml) at 10° C.
  • the mixture was stirred at 20° C. for 30 min and the layers were separated.
  • the water layer was extracted with toluene (4 ⁇ 150 ml).
  • Step D Preparation of 2-methoxy-(+)-4,5-seco-estr-9-en-3,5,17-trione,hydrolysis of the ketal
  • the reaction mixture was stirred at 40° C. for 2 h.
  • the reaction mixture was cooled to 20° C.
  • the water layer was extracted with dichloromethane (3 ⁇ 50 ml).
  • Step E Preparation and purification of 2-methoxy-estra-4,9-diene-3,17-dione, formation of the A-ring
  • Lithium (0.58 g) was slowly added to ethylene diamine (100 ml) at 100° C.
  • the crude product (6 g) was filtered over silica to remove the inorganic salts, yielding 1.7 g product.
  • the ratio of formed 9 ⁇ -H isomer to formed 9 ⁇ -H isomer was about 7:1.
  • the first organic layer (tetrahydrofuran/toluene) appeared to contain a considerable amount of product. After evaporation to dryness 250 mg product was obtained.
  • the ratio of formed 9a-H isomer to formed 9 ⁇ -H isomer was about 1:1.

Abstract

The invention provides a process for the preparation of 2-substituted-derivatives of estrone and estradiol comprising
  • i) the preparation of a compound of general formula (II) by reacting a compound of general formula (I)
Figure US20110152544A1-20110623-C00001
in one or more steps to a compound of general formula II
Figure US20110152544A1-20110623-C00002
wherein R1 is a C1-C10 alkyl, alkenyl or aryl group; —Cl, —Br, —I, —F; —CN; —OH; or a —OR2, —O(CO)R2 or —R2-OH group, wherein R2 is an alkyl or alkylene group having 1-6 C atoms; and the bonding between atoms 9 and 10 is a single or a double bond.
  • ii) aromatization of the compound of general formula II to a compound of general formula III
Figure US20110152544A1-20110623-C00003
wherein R1 and R2 have the above defined meanings; and
  • iii) optionally, reduction of the compound of general formula III to a compound of general formula IV
Figure US20110152544A1-20110623-C00004
wherein R1 and R2 have the above defined meanings.
Furthermore the invention provides several novel compounds, which can be intermediates in the above process, and processes to prepare these novel compounds.
The invention also provides 2-alkoxy-estrone, 2-alkoxy-estradiol or mixtures thereof essentially free from other estrogenic intermediates.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of U.S. Ser. No. 11/659,147 filed Feb. 1, 2007 which was a national stage application under 35 U.S.C. 371 of International Patent Application No.: PCT/EP2005/053732 filed Aug. 1, 2005, which claims the benefit of EP 04103742.5 filed Aug. 4, 2004, the disclosures of which are hereby incorporated by reference in their entirety.
  • TECHNICAL FIELD
  • This invention relates to a process for the preparation of 2-substituted-derivates of estrone and estradiol.
  • BACKGROUND OF THE INVENTION
  • The therapeutic value of 17-keto steroids or 17-hydroxy steroids such as estrone and estradiol are well known. In addition to the steroids itself, also derivatives of estrone and estradiol have been found to have therapeutic value. In this respect especially 2-alkoxy-derivates of estrone and estradiol, such as 2-methoxy-estradiol, need to be mentioned.
  • 2-methoxyestradiol, 1,3,5(10)-estratrien-2,3,17b-triol-2-methyl-ether (2-ME2) is an endogenous metabolite of estradiol. 2-ME2 has low estrogenic activity, but has been found to have important other biological effects, such as anti-cancer activity, as described herein below.
  • U.S. Pat. Nos. 5,504,074, 5,66,143 and 5,892,069 describe methods of treating mammalian diseases characterized by abnormal cell mitosis using 2-ME2. In addition WO-A-02/42319 describes 2-ME2 for the treatment of disease states characterized by abnormal angiogenesis.
  • Undesirable cell mitosis is characteristic of many diseases, including, but not limited to, cancer, atherosclerosis, proliferation of solid tumors, vascular malfunctions, endometriosis, retinopathies, arthropathies, and abnormal wound healing. In addition, cell mitosis is important in a wide variety of biological functions, including but not limited to the normal development of the embryo, formation of the corpus luteum, cyclic proliferation of uterine endometrium, wound healing and inflammatory and immune responses.
  • U.S. Pat. No. 5,521,168 describes the use of 2-ME2 for lowering intraocular pressure. 2-ME2 also inhibits estrogen-induced pituitary tumor angiogenesis and suppresses tumor growth in Fisher 344 rats as reported by Banerjee, S. K. et al., Proc. Amer. Assoc. Cancer Res. 39, March 1998.
  • Any therapeutic use of 2-ME2 in humans requires 2-ME2 having a high level of purity. In particular, since 2-ME2 has effects that are counteracted by estradiol and other estrogenic metabolites, it is desirable to have a 2-ME2 preparation substantially free of such contaminants. Effects that may be seen from contaminating estradiol, estrone and 2-hydroxtyestradiol include estrogenic effects such as feminization, endometrial proliferation, increased risk of uterine and breast cancer, developmental effects on sexual organs, inhibition of leucopoiesis and effects on haematopoietic cells. In addition, 4-hydroxyestradiol, 4-methoxyestradiol and estradiol are known to be at least suspected carcinogens.
  • These findings have prompted us to search for new synthetic procedures for the preparation of 2-alkoxy derivatives of estrone and estradiol such as 2-methoxyestradiol
  • Processes for the preparation of 2-ME2 are known in the art. For example, the article titled “Synthesis of 2-methoxyestrogens” by J. Fishman, published in the J. Am. Chem. Soc., 5 Mar. 1958, pages 1213-1216, describes the preparation of 2-methoxy-estradiol starting from estradiol. Also U.S. Pat. No. 6,051,726 describes the preparation of 2-alkoxyestradiols starting from estradiol. A disadvantage of such processes starting from estradiol, however, is the risk that the final product 2-ME2, will be contaminated with undesired estrogenically active compounds, such as the starting compound estradiol and/or any estrogenic intermediates. As explained above, such estrogenic impurities are highly undesirable.
  • EP-A-0776904 relates to the completely different technical field of the preparation of alkylketals of 3-keto-5(10),9(11)-gonadiene-derivatives. In its examples the preparation of such a gonadiene-derivative starting from estra-4,9-diene-3,17-dione is described. The estra-4,9-diene-3,17-dione compound is prepared by condensing (+)5α-hydroxy-7aβ-methyl-2,3,3aα,4,5,6,7,7a-octahydro-1H-inden-1-one-4α-(3-propionic acid)-lacton with 2-pentanone-neopentylacetale-5-magnesium chloride; oxidizing the 5α-hydroxy group; ring closure of the first ring (B); ketal cleavage; and ring closure of the second ring (A). EP-A-0776904 does not describe nor suggest the preparation of 2-substituted derivatives of estra-4,9-diene-3,17-dione.
  • Furthermore H. Ali et al, J. Chem. Soc. Perkin Trans. 1, 1991, page 2485-2491 describe the possibility of a route using 19-norsteroids with a suitable located double bond, followed by selective introduction of a functional group at position C2 or C4 and subsequent aromatization of the A-ring into 2- or 4-substituted-estradiol. No specific examples of such a 2-substitution according to this route were given.
  • Other preparations of 2-substituted estradiols are described in P. W. Le Quesne et al, Steroids, vol. 53/6, June 1989, page 649-661; L. R. Axelrod et al, Chem.&Ind., November 1959, page 1454-1455; and M. Mihailovic, Tetrahedron, vol. 33, 1977, page 235-237.
  • FIGURES
  • The following figures have been enclosed to illustrate the present invention:
  • FIG. 1: Reaction scheme for the preparation of 2-(3-chloro-1-methoxy-propyl)-2,5,5,-trimethyl-[1,3]dioxane.
  • FIG. 2: Reaction scheme for the preparation of 2-methoxy-estradiol.
  • SUMMARY OF THE INVENTION
  • Advantageously a new route to prepare 2-alkoxy-derivatives of estrone and estradiol has now been found. In addition this process can also be used for the preparation of other derivatives of estradiol and estrone.
  • In the newly found route, aromatisation of the A-ring is carried out in the last step of the synthesis. As a result, a final product is prepared essentially free from estrogenic intermediates. Advantageously the newly found route can start from sitolactone or a derivative thereof. Sitolactone is relatively inexpensive making such a route economically more attractive than for example the route described by J. Fishman.
  • Accordingly this invention provides a process for the preparation of 2-substituted-derivatives of estrone and estradiol comprising
  • i) the preparation of a compound of general formula (II) by reacting a compound of general formula (I)
  • Figure US20110152544A1-20110623-C00005
  • in one or more steps to a compound of general formula II
  • Figure US20110152544A1-20110623-C00006
  • wherein R1 is a C1-C10 alkyl, alkenyl or aryl group; —Cl, —Br, —I, —F; —CN; —OH; or a —OR2, —O(CO)R2 or —R2-OH group, wherein R2 is an alkyl or alkylene group having 1-6 C atoms; and the bonding between atoms 9 and 10 is a single or a double bond.
    ii) aromatization of the compound of general formula II to a compound of general formula III
  • Figure US20110152544A1-20110623-C00007
  • wherein R1 and R2 have the above defined meanings; and
    iii) optionally, reduction of the compound of general formula III to a compound of general formula IV
  • Figure US20110152544A1-20110623-C00008
  • wherein R1 and R2 have the above defined meanings.
  • Furthermore this invention provides several novel compounds, which can be intermediates in the above process, and processes to prepare these novel compounds.
  • Furthermore, as explained above, the process of the invention can be used to prepare 2-alkoxy-estrone or 2-alkoxy-estradiol, or mixtures thereof, containing essentially no estrogenic intermediates.
  • DETAILED DESCRIPTION OF THE INVENTION
  • As indicated above this invention provides a process for the preparation of estrone, estrone-derivates, estradiol and/or estradiol-derivates. The process is, however, especially advantageous for the preparation of 2-alkoxy derivatives of estrone and/or estradiol. In a specific embodiment, therefore, the present invention provides a process as described above for the preparation of 2-alkoxy derivatives of estrone and/or estradiol, i.e. estrone and/or estradiol substituted at position 2 with an alkoxy group. Moreover, the present invention provides such a process for the preparation of 2-methoxy-estrone and/or 2-methoxy-estradiol. As explained above such a process is especially advantageous because of the minimization of any estrogenic intermediates in the final product.
  • R1 in formulae II, III and IV can be a branched or straight alkyl group having from 1 to 10 carbon atoms, such as for example methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert.-butyl, pentyl, isopentyl, tert.-pentyl or neo-pentyl, hexyl, heptyl, octyl, nonyl or decyl. In a specific embodiment where R1 is an alkyl group, R1 is a methyl or ethyl group. Examples of groups where R1 is an alkenyl group include ethenyl, propenyl, iso-propenyl, butenyl and pentenyl. Examples of groups where R1 is an aryl group include phenyl, benzyl and tolyl.
  • In a specific embodiment of the invention R1 in formula II, III and IV is —OH; or an —OR2 group, wherein R2 is an alkyl group having 1 to 6 carbon atoms. In a further embodiment R1 is an C1-C6-alkoxy group, i.e. an —OR2 group, wherein R2 is a straight or branched alkyl group having 1 to 6 carbon atoms. Examples of such alkoxy groups include methoxy-, ethoxy-, propoxy-, isopropoxy-, butyloxy-, pentyloxy, hexyloxy-. In an even further embodiment R1 in formulae II, III and IV is a methoxy or ethoxy group, and in a still further embodiment R1 is a methoxy group.
  • When R1 is an alkoxy group, the invention provides a process for the preparation of 2-alkoxy estrone and/or 2-alkoxy-estradiol. By reducing 2-alkoxy-estrone, prepared according to step ii) of the process, 2-alkoxy-estradiol can be obtained.
  • The bonding between atoms 9 and 10 in formula II can be a single or a double bond. In a specific embodiment of this invention, however, the bonding between atoms 9 and 10 is a double bond.
  • The aromatization in step ii) of the compound of general formula II to the compound of general formula III, can be carried out in any manner known to the skilled person to be suitable for the process. Examples of such aromatization methods include the use of an aromatization agent such as potassium tert-pentoxide, and acetic anhydride; and the use of enzymes such as aromatase.
  • In a specific embodiment the aromatization is carried out by potassium pentoxide.
  • In another specific embodiment the aromatization is carried out by using lithium in ethylene diamine.
  • When the bonding between atoms 9 and 10 in formula II is a double bond, the aromatization can result in two isomers of the compound of general formula III, a 9-alfa-H- and a 9-beta-H-isomer. Of these, preparation of the naturally in the human body existing 9-alfa-H isomer is preferred. Advantageously aromatization of a compound of general formula II, wherein the bonding between atoms 9 and 10 is a double bond, with lithium in ethylene diamine results in a mixture of isomers comprising a majority of the 9-alfa-H isomer.
  • In a further embodiment the reaction is carried out in a suitable solvent. Examples of suitable solvents include diethyl amine, tetrahydrofuran; and mixtures thereof. The temperature during the reaction can vary widely. In one embodiment the reaction is carried out at a temperature in the range from 0° to 60° C. In a specific embodiment the reaction is carried out at room temperature (20-25° C.).
  • In a still further embodiment the mixture is subsequently quenched with a basic solution to remove residual starting material from the mixture via an acid-base extraction.
  • The reduction in step iii) of the compound of general formula III to the compound of general formula IV, can be carried out in any manner known by the skilled person to be suitable for this purpose. In one embodiment the reduction is carried out with the help of a reduction agent. Examples of suitable reduction agents include NaBH4 and LiAlH4. In a specific embodiment NaBH4 is used as a reduction agent. In a further embodiment the reaction is carried out in a suitable solvent. Examples of suitable solvents include alkanols such as methanol and ethanol; diethyl amine; tetrahydrofuran; and mixtures thereof. The temperature during the reaction can vary widely. In one embodiment the reaction is carried out at a temperature in the range from 0° to 70° C. In a specific embodiment the reaction is carried out at room temperature (20-25° C.)
  • Some of the compounds of general formula II are considered to be novel. Hence, this invention also provides a compound of general formula II
  • Figure US20110152544A1-20110623-C00009
  • wherein R1 and R2 are as specified herein above; and the bonding between atoms 9 and 10 is a single or a double bond.
  • In a specific embodiment R1 is a C1-C6-alkoxy group, i.e. an —OR2 group, wherein R2 is a straight or branched alkyl group having 1 to 6 carbon atoms. Examples of such alkoxy groups include methoxy-, ethoxy-, propoxy-, isopropoxy-, butyloxy-, pentyloxy, hexyloxy-. In an even further embodiment R1 in formulae II, III and IV is a methoxy or ethoxy group, and in a further embodiment R1 is a methoxy group.
  • Advantageously the compound of general formula II is prepared from a compound with formula I, also called sitolactone((4aS-(4aα,6aα,9aα,9bα))-decahydro-6a-methylcyclo-penta(f)(l)benzopyran-3,7-dione).
  • In a specific embodiment a compound with general formula II is prepared by a process comprising the steps of
  • a) reacting a compound of formula I
  • Figure US20110152544A1-20110623-C00010
  • with a compound of general formula V
  • Figure US20110152544A1-20110623-C00011
  • wherein R1 and R2 have the above defined meanings; R3 and R4 independently are an alkyl group comprising 1 to 6 carbon atoms; and X is chosen from Cl or Br;
  • to prepare a compound of general formula (VI)
  • Figure US20110152544A1-20110623-C00012
  • wherein R1, R2, R3 and R4, have the above defined meanings;
  • b) oxidizing the hydroxy group of the compound of general formula (VI) to generate a compound of general formula (VII)
  • Figure US20110152544A1-20110623-C00013
  • wherein R1, R2, R3 and R4, have the above defined meanings;
  • c) ring-closing of the B-ring of the compound of general formula VII to prepare a compound with general formula VIII
  • Figure US20110152544A1-20110623-C00014
  • wherein R1, R2, R3 and R4, have the above defined meanings;
  • d) reacting the compound of formula VIII in one or more steps to a compound of general formula II.
  • In a specific embodiment the coupling reaction in step a) is carried out with help of a Grignard reaction, wherein the compound of general formula V is first converted into a compound of general formula Va.
  • Figure US20110152544A1-20110623-C00015
  • Suitable solvents for this reaction include diethyl ether, tetrahydrofuran and mixtures thereof.
  • In a specific embodiment powdered magnesium is used, which is activated with dibromoethane, whereafter the compound of general formula V is added to prepare the compound of general formula Va. The latter is added portion wise into a solution or suspension comprising the compound of general formula I to generate a compound of general formula VI. In a further embodiment the reaction is carried out at refluxing temperature and at atmospheric pressure (1 bar). Preferably the obtained product is purified by crystallisation from a 1:1 mixture of heptane and ethyl acetate.
  • The oxidation of the hydroxy group of the compound of general formula VI to generate a compound of general formula VII in step b) can be carried out by any oxidation method known by the skilled person to be suitable for this purpose. Examples of suitable oxidation methods include the treatment with an oxidation agent such as chromic acid, chromium oxide/pyridine, chlorine/pyridine, calcium dichromate, pyridine chromates and N-bromosuccinimide; and the Oppenauer oxidation. In one specific embodiment the oxidation is carried out by oxidation with chromic acid in acetone. In a second embodiment the oxidation is carried out with tetra-n-propyl ammonium perruthenate (TPAP) and N-methylmorpholine N-oxide (NMO). As an alternative solvent dichloromethane can be used.
  • The ring-closing of the B-ring of the compound of general formula VII to prepare a compound with general formula VIII in step c) can be carried out in any manner known by the skilled person to be suitable for this purpose. By the B-ring is understood those carbon atoms that form the B-ring in the final product estrone- or estradiol derivate. In one specific embodiment the ring-closing step is carried out by an aldol condensation under alkaline conditions, which condensation is in a further embodiment followed by a dehydration of the aldol product. Examples of suitable bases that can be used include potassium-tert-butoxide, potassium-tert-pentoxide, sodium hydroxide, potassium hydroxide. The skilled person will further recognize that many more bases can be used. In a further embodiment the reaction is carried out in a suitable solvent. Examples of suitable solvents include toluene; alkanols such as methanol, ethanol and isopropanol; tetrahydrofuran; and mixtures thereof. In a specific embodiment a mixture of methanol, toluene and water is used as a solvent. The temperature during the reaction can vary widely. In one embodiment the reaction is carried out at a temperature in the range from 0° to 80° C. In a specific embodiment the reaction is carried out at room temperature (20°-25° C.). In another specific embodiment the reaction is carried out at a temperature in the range from 55° to 75° C. In a further embodiment the obtained compound of general formula VIII is purified by crystallisation from a suitable solvent such as an alcohol. In a specific embodiment the compound of general formula VIII is purified by crystallisation in isopropanol.
  • The preparation of a compound of general formula II from the compound of general formula VIII according to step d) can be carried out by any manner known by the skilled person to be suitable for this purpose. In one specific embodiment the reaction of step d) comprises
  • d1) hydrolysis of a compound of general formula VIII, wherein the bonding between atoms 9 and 10 is a double bond, to obtain a compound of general formula IX,
  • Figure US20110152544A1-20110623-C00016
  • wherein R1 and R2 have the above defined meanings;
  • d2) ring-closure of the A-ring to obtain a compound of general formula II, wherein the dotted bonding between atoms 9 and 10 is a double bond, from the compound of general formula IX.
  • In an alternative embodiment the reaction of step d) comprises
  • d3) hydrogenation of the double bond between atoms 9 and 10 of the compound of general formula VIII to obtain a compound of general formula X;
  • Figure US20110152544A1-20110623-C00017
  • d4) hydrolysis of the compound of general formula X to obtain a compound of general formula XI;
  • Figure US20110152544A1-20110623-C00018
  • d5) ring-closure of the A-ring in the compound of general formula XI, to obtain a compound of general formula II, wherein the dotted bonding between atoms 9 and 10 is a single bond.
  • By the A-ring is understood those carbon atoms that form the A-ring in the final product estrone- or estradiol derivate.
  • The hydrolysis of step d1) can be carried out in any manner known by the skilled person to be suitable for this purpose. In one embodiment the hydrolysis is carried out under acidic conditions. Examples of suitable hydrolysis agents include hydrohalogens, phosphoric acids, sulfonic and sulfuric acids, such as hydrochloric acid, sulfuric acid, para-toluene sulfonic acid and phosphoric acid. In one embodiment sulfuric acid (H2SO4) is used as a hydrolysis agent. Any solvent known by the skilled person to be suitable for this purpose can be used as solvent during the reaction. Examples of suitable solvents include C1-C6 alkanols, such as methanol, ethanol, propanol and isopropanol. In one embodiment ethanol is used as a solvent. The temperature during the reaction can vary widely. In one embodiment the reaction is carried out at a temperature in the range from 0° to 40° C., and in a specific embodiment the reaction is carried out at room temperature (20°-25° C.).
  • The ring-closure of the A-ring of step d2) can be carried out in any manner known by the skilled person to be suitable for this purpose. In one specific embodiment the ring-closing step is carried out by an aldol condensation under alkaline conditions, which condensation is in a further embodiment followed by a dehydration of the aldol product. Examples of suitable bases that can be used include potassium-tert-butoxide, potassium-tert-pentoxide, sodium hydroxide, potassium hydroxide. The skilled person will further recognize that many more bases can be used. In a further embodiment the reaction is carried out in a suitable solvent. Examples of suitable solvents include toluene; alkanols such as methanol, ethanol and isopropanol; tetrahydrofuran; and mixtures thereof. The temperature during the reaction can vary widely. In one embodiment the reaction is carried out at a temperature in the range from 0° to 80° C. In a specific embodiment the reaction is carried out at room temperature (20°-25° C.).
  • The hydrogenation of step d3) can be carried out in any manner known by the skilled person to be suitable for this purpose. In one embodiment Pd/C and hydrogen are used for the hydrogenation. In a further embodiment the reaction is carried out in a suitable solvent. Examples of suitable solvents include tetrahydrofuran; alkanols such as methanol, ethanol and isopropanol; and mixtures thereof. In a specific embodiment ethanol is used as a solvent. The temperature during the reaction can vary widely. In one embodiment the reaction is carried out at a temperature in the range from 0° to 80° C. In a specific embodiment the reaction is carried out at a temperature in the range from 25° to 60° C.
  • The hydrolysis of step d4) can be carried out in any manner known by the skilled person to be suitable for this purpose. In one embodiment the hydrolysis is carried out under acidic conditions. Examples of suitable hydrolysis agents include hydrohalogens, phosphoric acids, sulfonic and sulfuric acids, such as hydrochloric acid, sulfuric acid, para-toluene sulfonic acid and phosphoric acid. In one embodiment sulfuric acid (H2SO4) is used as a hydrolysis agent. Any solvent known by the skilled person to be suitable for this purpose can be used as solvent during the reaction. Examples of suitable solvents include C1-C6 alkanols, such as methanol, ethanol, propanol and isopropanol. In one embodiment ethanol is used as a solvent. The temperature during the reaction can vary widely. In one embodiment the reaction is carried out at a temperature in the range from 0° to 40° C., and in a specific embodiment the reaction is carried out at room temperature (20°-25° C.).
  • The ring-closure of the A-ring of step d5) can be carried out in any manner known by the skilled person to be suitable for this purpose. In one specific embodiment the ring-closing step is carried out by an aldol condensation under alkaline conditions, which condensation is in a further embodiment followed by a dehydration of the aldol product. Examples of suitable bases that can be used include potassium-tert-butoxide, potassium-tert-pentoxide, sodium hydroxide, potassium hydroxide. The skilled person will further recognize that many more bases can be used. In a further embodiment the reaction is carried out in a suitable solvent. Examples of suitable solvents include toluene; alkanols such as methanol, ethanol and isopropanol; tetrahydrofuran; and mixtures thereof. The temperature during the reaction can vary widely. In one embodiment the reaction is carried out at a temperature in the range from 0° to 80° C. In a specific embodiment the reaction is carried out at room temperature (20°-25° C.).
  • A number of the above mentioned intermediates are considered novel. Hence the present invention also provides a compound of general formula V
  • Figure US20110152544A1-20110623-C00019
  • and its Mg activated counterpart of general formula Va
  • Figure US20110152544A1-20110623-C00020
  • wherein R1, R2, R3 and R4, have the above defined meanings; and X is chosen from Cl or Br. In a further embodiment R3 and R4 are independently methyl or ethyl groups. In a specific embodiment R3 and R4 are methyl groups and R1 is a methoxy group. Examples of suitable compounds according to general formula V include for example 2-(3-chloro-1-methoxy-propyl)-2,5,5-trimethyl-[1,3]dioxane and 2-(3-bromo-1-methoxy-propyl)-2,5,5-trimethyl-[1,3]dioxane. Examples of suitable compounds according to general formula Va include for example 3-methoxy-2-pentanone-neopentylacetale-5-magnesium chloride and 3-methoxy-2-pentanone-neopentylacetale-5-magnesium bromide.
  • The compounds of general formula (V) can for example be prepared by halogenation of a suitably substituted propene compound; substitution of one halogen atom by a nitrile group; addition of a methyl group by a grignard reaction and conversion into the 5-chloro-pentan-2-one compound substituted at its 3 position by an appropriate group; and reaction with neopentylglycol under acidic conditions to obtain the compound of general formula (V). The preparation of 2-(3-chloro-1-methoxy-propyl)-2,5,5-trimethyl-[1,3]dioxane is illustrated in FIG. 1.
  • Furthermore the invention provides a compound of general formula (VI)
  • Figure US20110152544A1-20110623-C00021
  • wherein R1, R2, R3 and R4, have the above defined meanings.
  • Even further the invention provides a compound of general formula VII
  • Figure US20110152544A1-20110623-C00022
  • wherein R1, R2, R3 and R4, have the above defined meanings.
  • Even further the invention provides a compound with general formula VIII
  • Figure US20110152544A1-20110623-C00023
  • wherein R1, R2, R3 and R4, have the above defined meanings.
  • Even further the invention provides a compound of general formula IX,
  • Figure US20110152544A1-20110623-C00024
  • wherein R1 and R2 have the above defined meanings.
  • Even further the invention provides a compound of general formula X,
  • Figure US20110152544A1-20110623-C00025
  • wherein R1, R2, R3 and R4 are as defined above.
  • Even further the invention provides a compound of general formula XI
  • Figure US20110152544A1-20110623-C00026
  • wherein R1 and R2 are as defined above.
  • The invention is illustrated by the following non-limiting examples and the reaction scheme in FIG. 2.
  • Example 1 Step A: Preparation of (3aα,4β,5α,7aβ)-5-hydroxy-7a-methyl-4[7-(2,5,5-trimethyl-1,3-dioxan-2-yl)-5-methoxy-3-oxohexyl]-1H-inden-1-one
  • Magnesium powder 50 Mesh (10 g) was suspended in dry tetrahydrofuran (70 ml). The suspension was heated up to 50° C. After adding dibromoethane (500 μl), a vigorous reaction occurred. An initial portion of 2-(3-chloro-1-methoxy-propyl)-2,5,5-trimethyl-[1,3]dioxane (2 g) was added. After 1 h stirring at reflux 2-(3-chloro-1-methoxy-propyl)-2,5,5-trimethyl-[1,3]dioxane (35 g) was added. After stirring at reflux for 20 h the reaction mixture was cooled to 20° C.
  • The unreacted magnesium was allowed to settle down and the upper layer was taken up in a syringe and added to a suspension of (4aS-(4aα,6aα,9aα,9bβ))-decahydro-6a-methylcyclo-penta(f)(l)benzopyran-3,7-dione (sitolactone, 28 g) in tetrahydrofuran (110 ml) at −35° C.
  • After stirring for 4 h at −30° C. the temperature was increased to 20° C. in 1 h.
  • A solution of ammonium chloride (10 g in 200 ml water) was added drop wise to the reaction mixture in 40 min.
  • The suspension was stirred for 1 h and filtered over a Dicalite® filter.
  • The filter was washed with dichloromethane (2×100 ml).
  • After a solvent free distillation in vacuo at 30° C., the residue was extracted with dichloromethane (5×100 ml).
  • The organic layers were combined and concentrated in vacuo at 30° C.
  • After drying 51.6 g crude (3aα,4β,5α,7aβ)5-hydroxy-7a-methyl-4[7-(2,5,5-trimethyl-1,3-dioxan-2-yl)-5-methoxy-3-oxohexyl]-1H-inden-1-one was obtained.
  • Example 2 Step B: Preparation of (3aα,4β,5α,7aβ)-5-oxo-7a-methyl-4[6-(2,5,5-trimethyl-1,3-dioxan-2-yl)-5-methoxy-3-oxohexyl]-1H-inden-1-one, oxidation of the hydroxy group
  • To a solution of (3aα,4β,5α,7β)-5-hydroxy-7a-methyl-4[7-(2,5,5-trimethyl-1,3-dioxan-2-yl)-5-methoxy-3-oxohexyl]-1H-inden-1-one (85 g) in dichloromethane (450 ml), N-methylmorpholine (35 g) and tetrapropyl ammoniumperruthenate (2 g) were added at 20° C.
  • After stirring at 20° C. for 20 h silica (50 g) was added. The reaction mixture was filtered over a Dicalite® filter with silica and the filter was washed with dichloromethane (500 ml).
  • The filtrate was evaporated to dryness at 30° C. 75.36 g crude (3aα,4β,5α,7aβ)-5-oxo-7a-methyl-4[6-(2,5,5-trimethyl-1,3-dioxan-2-yl)-5-methoxy-3-oxohexyl]-1H-inden-1-one was obtained containing about 10% starting material.
  • Example 3 Step C: Preparation of (3aα,9aα,9bβ)-4,5,8,9,9a,9b-hexahydro-3a-methyl-6-(2-(2,5,5-trimethyl-1,3-dioxan-2-yl)-1-methoxy-ethyl)-1H-benz(e)indene-3,7(2H,3aH)-dione, formation of the B-ring
  • Potassium tert-butoxide (6.4 g) was suspended in toluene (100 ml) and 2-propanol (32 ml) at 20° C.
  • A solution of (3aα,4β,5α-7aβ)-5-oxo-7a-methyl-4[6-(2,5,5-trimethyl-1,3-dioxan-2-yl)-5-methoxy-3-oxohexyl]-1H-inden-1-one (80 g) in toluene (400 ml) was added to the Potassium tert-butoxide/toluene/2-propanol mixture in 30 min.
  • After stirring the reaction mixture for 2 h at 20° C., the reaction mixture was acidified with acetic acid (8 ml) to pH 4.
  • After adding water (300 ml) and stirring for 15 min at 20° C., the layers were separated.
  • The water layer was extracted with toluene (3×100 ml) and the combined organic layer was extracted with a solution of sodium hydroxide (5 g) in water (100 ml). The organic layer was evaporated to dryness in vacuo at 50° C.
  • The residue was dissolved in 2-propanol (300 ml) at 50° C. and the solution was cooled to 10° C.
  • After stirring for 2 h at 10° C. a first crop of white crystals (7.8 g) was obtained.
  • The mother liquor was evaporated to dryness and taken up in heptane (50 ml).
  • The solution was stirred at 70° C. for 30 min and then cooled to 20° C.
  • After stirring the suspension at 20° C. for 50 h, a second crop of white crystals (11.5 g) was obtained.
  • Example 4 Step B and C: Preparation of (3aα,9aα,9bβ)-4,5,8,9,9a,9b-hexahydro-3a-methyl-6-(2-(2,5,5-trimethyl-1,3-dioxan-2-yl)-1-methoxy-ethyl)-1H-benz(e)indene-3,7(2H,3aH)-dione; Combined oxidation and aldol condensation
  • A solution of (3aα,4β,5α,7β)-5-hydroxy-7a-methyl-4[7-(2,5,5-trimethyl-1,3-dioxan-2-yl)-5-methoxy-3-oxohexyl]-1H-inden-1-one (147 g) in a mixture of toluene (690 ml) and pyridine (162 ml) was cooled to −2° C.
  • Chlorine gas (42 g) was led into the reaction mixture in 2 h.
  • After stirring the reaction mixture at −2° C. for 2 h, the reaction mixture was poured into a solution of sodium sulfite (93 g) and sodium carbonate (78 g) in water (750 ml) at 10° C.
  • The mixture was stirred at 20° C. for 30 min and the layers were separated. The water layer was extracted with toluene (4×150 ml).
  • The combined organic layer was evaporated to dryness in vacuo at 50° C.
  • The residue was dissolved in toluene (660 ml).
  • A solution of potassium hydroxide (127.5 g) in water (185 ml) and methanol (430 ml) was added to the toluene solution.
  • After stirring at 65° C. for 45 min the reaction mixture was cooled to 20° C.
  • The layers were separated and the organic layer was washed with 50% methanol (aq) (2×175 ml). The combined methanol/water extracts were washed with dichloromethane (4×100 ml).
  • The combined organic layer was evaporated to dryness in vacuo at 40° C. and the residue was suspended in 2-propanol (250 ml) at 50° C.
  • After stirring at 50° C. for 15 min the suspension was stirred for 1 h at 10° C. and the crystals were filtered off and washed with 2-propanol (2×10 ml).
  • After drying 58.04 g product was obtained.
  • Example 5 Step D: Preparation of 2-methoxy-(+)-4,5-seco-estr-9-en-3,5,17-trione,hydrolysis of the ketal
  • To a suspension of (3aα,9aα,9β)-4,5,8,9,9a,9b-hexahydro-3a-methyl-6-(2,5,5-trimethyl-1,3-dioxan-2-yl)-1-methoxy-ethyl)-1H-benz(e)indene-3,7(2H,3aH)-dione (16.2 g) in ethanol (200 ml) sulfuric acid (2 ml) was added to the suspension (pH=2) at 20° C.
  • The reaction mixture was stirred at 40° C. for 2 h.
  • A solution of sodium acetate (3.5 g) in water (100 ml) was added to the reaction mixture.
  • The reaction mixture was cooled to 20° C.
  • After adding dichloromethane (100 ml) and water (100 ml) the mixture was stirred for 30 min at 20° C. and the layers were separated.
  • The water layer was extracted with dichloromethane (3×50 ml).
  • The dichloromethane extracts were combined and evaporated to dryness at 50° C., obtaining 16.7 g crude product.
  • Example 6 Step E: Preparation and purification of 2-methoxy-estra-4,9-diene-3,17-dione, formation of the A-ring
  • A solution of 2-methoxy-(+)-4,5-seco-estr-9-en-3,5,17-trione (10 g) in tetrahydrofuran (50 ml) was added in 30 min to a suspension of Potassium tert-butoxide (750 mg) in tetrahydrofuran (50 ml) at 20° C.
  • After stirring at 20° C. for 7 h the reaction mixture was neutralized to pH=6 with 4.0 N sulfuric acid.
  • The reaction mixture was concentrated in vacuo at 35° C.
  • The residue was dissolved in dichloromethane (100 ml) and extracted with water (2×50 ml).
  • The organic layer was evaporated to dryness at 35° C. and 8.1 g crude product was obtained.
  • Example 7 Step F: Preparation of 2-methoxy-estrone, aromatisation
  • Lithium (0.58 g) was slowly added to ethylene diamine (100 ml) at 100° C.
  • After stirring the mixture for 30 min at 100° C. it was cooled to 20° C.
  • A solution of 2-methoxy-estra-4,9-diene-3,17-dione (5 g) in ethylene diamine (20 ml) was added in 30 min to the reagent at 20° C.
  • After stirring for 3 h at 20° C. the reaction mixture was poured into water (250 ml).
  • It was acidified with sulfuric acid to pH=7.
  • After stirring for 12 h at 20° C. light brown crystals were obtained and filtered off.
  • The crude product (6 g) was filtered over silica to remove the inorganic salts, yielding 1.7 g product. The ratio of formed 9α-H isomer to formed 9β-H isomer was about 7:1.
  • Example 8 Step F: Preparation of 2-methoxy-estrone, aromatisation
  • At 20° C. 2-methoxy-estra-4,9-diene-3,17-dione (500 mg, 1.66 mmol) was dissolved in tetrahydrofuran (12.5 ml). Hereafter a solution of 1.7 M potassium tert-pentoxide in toluene (5 ml toluene, 8.5 mmol potassium tert-pentoxide) was added. The reaction was quenched with 25 ml of a 1M Sodium hydroxide (NaOH) solution. The aqueous layer was separated and the pH was brought to 4 with 2M sulfuric acid. After extraction with three portions of dichloromethane (15 ml), 200 mg crude product was obtained via evaporation to dryness of the organic layer.
  • The first organic layer (tetrahydrofuran/toluene) appeared to contain a considerable amount of product. After evaporation to dryness 250 mg product was obtained.
  • The ratio of formed 9a-H isomer to formed 9β-H isomer was about 1:1.
  • Example 9 Step G: Preparation of 2-methoxy-estradiol, reduction
  • To a solution of 2-methoxyestrone (2 g) in tetrahydrofuran (15 ml) 33% sodium hydroxide (200 μl) and water (2 ml) were added at 20° C.
  • Sodium borohydride (0.25 g) was slowly added to the reaction mixture.
  • The reaction mixture was stirred for 1 h at 20° C. and neutralized with acetic acid to pH=7.
  • After stirring for 30 min the layers were separated and the water layer was extracted with dichloromethane (2×10 ml).
  • The organic layers were combined and evaporated to dryness at 35° C.
  • The residue (2.1 g) was chromatographed over silica (200 g) with a mixture of toluene and ethyl acetate (volume-ratio of toluene to ethyl acetate 9:1).
  • Crystallizations from acetone and ethanol yielded 400 mg 2-methoxyestradiol.

Claims (17)

1. Process for the preparation of 2-substituted-derivatives of estrone and estradiol comprising
i) the preparation of a compound of general formula (II) by reacting a compound of general formula (I)
Figure US20110152544A1-20110623-C00027
in one or more steps to a compound of general formula II
Figure US20110152544A1-20110623-C00028
wherein R1 is a C1-C10 alkyl, alkenyl or aryl group; —Cl, —Br, —I, —F; —CN; —OH; or a —OR2, —O(CO)R2 or —R2-OH group, wherein R2 is an alkyl or alkylene group having 1-6 C atoms; and the bonding between atoms 9 and 10 is a single or a double bond.
ii) aromatization of the compound of general formula II to a compound of general formula III
Figure US20110152544A1-20110623-C00029
wherein R1 and R2 have the above defined meanings; and
iii) optionally, reduction of the compound of general formula III to a compound of general formula IV
Figure US20110152544A1-20110623-C00030
wherein R1 and R2 have the above defined meanings.
2. Process according to claim 1, wherein in the compounds of general formulae II, III, and IV R1 is an —OR2 group, wherein R2 is an alkyl group having 1 to 6 carbon atoms.
3. Process according to claim 1 or 2, wherein in the compound of general formula II the bonding between atoms 9 and 10 is a double bond.
4. Process according to anyone of claims 1-3, wherein the aromatization in step ii) is carried with the help of lithium in ethylene diamine.
5. Process according to anyone of claims 1-4, wherein the reduction in step iii) is carried out using NaBH4 as a reduction agent.
6. Compound of general formula II
Figure US20110152544A1-20110623-C00031
wherein R1 is a C1-C10 alkyl, alkenyl or aryl group; —Cl, —Br, —I, —F; —CN; —OH; or a —OR2, —O(CO)R2 or —R2-OH group, wherein R2 is an alkyl or alkylene group having 1-6 C atoms; and the bonding between atoms 9 and 10 is a single or a double bond.
7. Process for the preparation of a compound of general formula II,
Figure US20110152544A1-20110623-C00032
wherein R1 is a C1-C10 alkyl, alkenyl or aryl group; —Cl, —Br, —I, —F; —CN; —OH; or a —OR2, —O(CO)R2 or —R2-OH group, wherein R2 is an alkyl or alkylene group having 1-6 C atoms; and the bonding between atoms 9 and 10 is a single or a double bond;
comprising the steps of
a) reacting a compound of formula I
Figure US20110152544A1-20110623-C00033
with a compound of general formula V
Figure US20110152544A1-20110623-C00034
wherein R1 and R2 have the above defined meanings; R3 and R4 independently are an alkyl group comprising 1 to 6 carbon atoms; and X is chosen from Cl or Br;
to prepare a compound of general formula (VI)
Figure US20110152544A1-20110623-C00035
wherein R1, R2, R3 and R4, have the above defined meanings;
b) oxidizing the hydroxy group of the compound of general formula (VI) to generate a compound of general formula (VII)
Figure US20110152544A1-20110623-C00036
wherein R1, R2, R3 and R4, have the above defined meanings;
c) ring-closing of the B-ring of the compound of general formula VII to prepare a compound with general formula VIII
Figure US20110152544A1-20110623-C00037
wherein R1, R2, R3 and R4, have the above defined meanings;
d) reacting the compound of formula VIII in one or more steps to a compound of general formula II.
8. Process according to claim 7, wherein the reaction of step d) comprises
d1) hydrolysis of a compound of general formula VIII, wherein the bonding between atoms 9 and 10 is a double bond, to obtain a compound of general formula IX,
Figure US20110152544A1-20110623-C00038
wherein R1 is a C1-C10 alkyl, alkenyl or aryl group; —Cl, —Br, —I, —F; —CN; —OH; or a —OR2, —O(CO)R2 or —R2-OH group, wherein R2 is an alkyl or alkylene group having 1-6 C atoms;
d2) ring-closure of the A-ring to obtain a compound of general formula II, wherein the bonding between atoms 9 and 10 is a double bond, from the compound of general formula IX.
9. Process according to claim 7, wherein the reaction of step d) comprises
d3) hydrogenation of the double bond between atoms 9 and 10 of the compound of general formula VIII to obtain a compound of general formula X;
Figure US20110152544A1-20110623-C00039
d4) hydrolysis of the compound of general formula X to obtain a compound of general formula XI;
Figure US20110152544A1-20110623-C00040
d5) ring-closure of the A-ring in the compound of general formula XI, to obtain a compound of general formula II, wherein the bonding between atoms 9 and 10 is a single bond.
10. Compound of general formula V
Figure US20110152544A1-20110623-C00041
wherein R1 is a C1-C10 alkyl, alkenyl or aryl group; —Cl, —Br, —I, —F; —CN; —OH; or a —OR2, —O(CO)R2 or —R2-OH group, wherein R2 is an alkyl or alkylene group comprising 1 to 6 carbon atoms; R3 and R4 independently are an alkyl group comprising 1 to 6 carbon atoms; and X is chosen from Cl or Br;
11. Compound of general formula (VI)
Figure US20110152544A1-20110623-C00042
wherein R1 is a C1-C10 alkyl, alkenyl or aryl group; —Cl, —Br, —I, —F; —CN; —OH; or a —OR2, —O(CO)R2 or —R2-OH group, wherein R2 is an alkyl or alkylene group comprising 1 to 6 carbon atoms; R3 and R4 independently are an alkyl group comprising 1 to 6 carbon atoms.
12. Compound of general formula (VII)
Figure US20110152544A1-20110623-C00043
wherein R1 is a C1-C10 alkyl, alkenyl or aryl group; —Cl, —Br, —I, —F; —CN; —OH; or a —OR2, —O(CO)R2 or —R2-OH group, wherein R2 is an alkyl or alkylene group comprising 1 to 6 carbon atoms; R3 and R4 independently are an alkyl group comprising 1 to 6 carbon atoms.
13. Compound of general formula VIII
Figure US20110152544A1-20110623-C00044
wherein R1 is a C1-C10 alkyl, alkenyl or aryl group; —Cl, —Br, —I, —F; —CN; —OH; or a —OR2, —O(CO)R2 or —R2-OH group, wherein R2 is an alkyl or alkylene group comprising 1 to 6 carbon atoms; R3 and R4 independently are an alkyl group comprising 1 to 6 carbon atoms.
14. Compound of general formula IX,
Figure US20110152544A1-20110623-C00045
wherein R1 is a C1-C10 alkyl, alkenyl or aryl group; —Cl, —Br, —I, —F; —CN; —OH; or a —OR2, —O(CO)R2 or —R2-OH group, wherein R2 is an alkyl or alkylene group comprising 1 to 6 carbon atoms.
15. Compound of general formula X,
Figure US20110152544A1-20110623-C00046
wherein R1 is a C1-C10 alkyl, alkenyl or aryl group; —Cl, —Br, —I, —F; —CN; —OH; or a —OR2, —O(CO)R2 or —R2-OH group, wherein R2 is an alkyl or alkylene group comprising 1 to 6 carbon atoms; R3 and R4 independently are an alkyl group comprising 1 to 6 carbon atoms.
16. Compound of general formula XI,
Figure US20110152544A1-20110623-C00047
wherein R1 is a C1-C10 alkyl, alkenyl or aryl group; —Cl, —Br, —I, —F; —CN; —OH; or a —OR2, —O(CO)R2 or —R2-OH group, wherein R2 is an alkyl or alkylene group comprising 1 to 6 carbon atoms.
17. 2-alkoxy-estrone, 2-alkoxy-estradiol or mixtures thereof essentially free from estrogenic intermediates.
US13/031,975 2004-08-04 2011-02-22 Process for the preparation 2-substituted derivatives of estrone and estradiol Abandoned US20110152544A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/031,975 US20110152544A1 (en) 2004-08-04 2011-02-22 Process for the preparation 2-substituted derivatives of estrone and estradiol

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP04103742.5 2004-08-04
EP04103742 2004-08-04
PCT/EP2005/053732 WO2006013196A1 (en) 2004-08-04 2005-08-01 Process for the preparation 2-substituted-derivatives of estrone and estradiol
US65914707A 2007-02-01 2007-02-01
US13/031,975 US20110152544A1 (en) 2004-08-04 2011-02-22 Process for the preparation 2-substituted derivatives of estrone and estradiol

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2005/053732 Continuation WO2006013196A1 (en) 2004-08-04 2005-08-01 Process for the preparation 2-substituted-derivatives of estrone and estradiol
US65914707A Continuation 2004-08-04 2007-02-01

Publications (1)

Publication Number Publication Date
US20110152544A1 true US20110152544A1 (en) 2011-06-23

Family

ID=34929415

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/659,147 Expired - Fee Related US7910756B2 (en) 2004-08-04 2005-08-01 Process for the preparation 2-substituted-derivatives of estrone and estradiol
US13/031,975 Abandoned US20110152544A1 (en) 2004-08-04 2011-02-22 Process for the preparation 2-substituted derivatives of estrone and estradiol

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US11/659,147 Expired - Fee Related US7910756B2 (en) 2004-08-04 2005-08-01 Process for the preparation 2-substituted-derivatives of estrone and estradiol

Country Status (20)

Country Link
US (2) US7910756B2 (en)
EP (1) EP1776378B1 (en)
JP (1) JP5075626B2 (en)
KR (1) KR20070040386A (en)
CN (1) CN1993376A (en)
AR (1) AR050195A1 (en)
AT (1) ATE447580T1 (en)
AU (1) AU2005268768B2 (en)
BR (1) BRPI0514096A (en)
CA (1) CA2573133C (en)
DE (1) DE602005017500D1 (en)
EC (1) ECSP077228A (en)
ES (1) ES2334244T3 (en)
IL (1) IL180381A0 (en)
MX (1) MX2007001340A (en)
NO (1) NO20070747L (en)
RU (1) RU2007107914A (en)
TW (1) TW200611909A (en)
WO (1) WO2006013196A1 (en)
ZA (1) ZA200700483B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2742352A4 (en) * 2011-08-12 2015-05-13 Siemens Healthcare Diagnostics Detection of sex steroids

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2008275A3 (en) 2008-05-05 2009-05-06 Prírodovedecká Fakulta Uk Estrogen receptors alpha and beta ligands, method of their preparation and pharmaceutical compositions comprising thereof
WO2012020417A1 (en) 2010-08-10 2012-02-16 Reliance Life Sciences Pvt. Ltd. Process for the preparation of estradiol and its derivatives
CN104497088B (en) * 2014-12-30 2016-08-24 湖南新合新生物医药有限公司 The preparation method of 19-nor--4-androstene-3,17-diketone
CN104592339A (en) * 2014-12-30 2015-05-06 湖南新合新生物医药有限公司 Preparation method of estra-4, 9-diene-3,17-diketone
ITUB20155260A1 (en) * 2015-10-30 2017-04-30 Ind Chimica Srl PROCESS FOR THE PREPARATION OF 17? -Hydroxy-des-A-androst-9,10-en-5-one
CN108003210A (en) * 2018-01-24 2018-05-08 四川理工学院 A kind of preparation method of female steroid -4,9- diene -3,17- diketone
CN108997463B (en) * 2018-08-09 2021-05-14 四川理工学院 Preparation method of estra-4, 9-diene-3, 17-dione
CN112409434B (en) * 2020-11-27 2021-10-26 厦门欧瑞捷生物科技有限公司 Synthesis method of dehydroprogesterone
CN113861158B (en) * 2021-11-22 2023-02-10 湖南新合新生物医药有限公司 Method for synthesizing methyl diene diketone key intermediate
CN114853802B (en) * 2022-03-22 2023-11-28 河北康泰药业有限公司 Gluconolide derivative and preparation method, pharmaceutical composition and application thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3186907A (en) * 1961-04-14 1965-06-01 Roussel Uclaf 19-nor-testosterone derivatives, their process of preparation and their method of utilization
US3519714A (en) * 1966-03-15 1970-07-07 Herchel Smith Synthesis of gona-1,3,5(10)-trienes
US4400524A (en) * 1981-07-28 1983-08-23 The Upjohn Company Grignard reagents prepared from 5-halopentan-2-one propylene ketals
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US5521168A (en) * 1994-10-13 1996-05-28 Alcon Laboratories, Inc. Estrogen metabolites for lowering intraocular pressure
US5998639A (en) * 1995-11-06 1999-12-07 Akzo Nobel, N.V. Sulfatation of estrogen mixtures
US6051726A (en) * 1997-03-13 2000-04-18 Pharm-Eco Laboratories, Inc. Synthesis of 2-alkoxyestradiols
US20040097479A1 (en) * 1999-08-23 2004-05-20 Agoston Gregory E. Methods of obtaining 2-methoxyestradiol of high purity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2997488A (en) * 1959-06-20 1961-08-22 Organon 2-methyl-19-nor-steroids
FR1468608A (en) * 1960-08-04 1967-02-10 Upjohn Co 2-alpha-fluoro steroids of the 19-norandrostene series and their production process
BE616293A (en) 1961-04-14 1962-10-11 Roussel Uclaf 19-nor testosterone derivatives and method of preparation
DE3208432A1 (en) 1982-03-09 1983-09-15 The Upjohn Co., 49001 Kalamazoo, Mich. Process for the preparation of 19-norandrostenedione, intermediate of 19-norandrostenedione and processes for its preparation
IL119649A (en) * 1995-11-30 2002-03-10 Akzo Nobel Nv Preparation of cyclic ketals of 3-keto-5(10), 9(11)-steroid diene derivatives
CA2376297A1 (en) 1999-08-23 2001-03-01 Gregory E. Agoston Methods of obtaining 2-methoxyestradiol of high purity
CA2430100A1 (en) 2000-11-27 2002-05-30 Entremed, Inc. Antiangiogenic agents

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3186907A (en) * 1961-04-14 1965-06-01 Roussel Uclaf 19-nor-testosterone derivatives, their process of preparation and their method of utilization
US3519714A (en) * 1966-03-15 1970-07-07 Herchel Smith Synthesis of gona-1,3,5(10)-trienes
US4400524A (en) * 1981-07-28 1983-08-23 The Upjohn Company Grignard reagents prepared from 5-halopentan-2-one propylene ketals
US5892069A (en) * 1993-08-06 1999-04-06 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
US5661143A (en) * 1993-08-06 1997-08-26 The Children's Medical Center Corp. Estrogenic compounds as anti-mitotic agents
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US5521168A (en) * 1994-10-13 1996-05-28 Alcon Laboratories, Inc. Estrogen metabolites for lowering intraocular pressure
US5998639A (en) * 1995-11-06 1999-12-07 Akzo Nobel, N.V. Sulfatation of estrogen mixtures
US6051726A (en) * 1997-03-13 2000-04-18 Pharm-Eco Laboratories, Inc. Synthesis of 2-alkoxyestradiols
US20040097479A1 (en) * 1999-08-23 2004-05-20 Agoston Gregory E. Methods of obtaining 2-methoxyestradiol of high purity
US20060025619A1 (en) * 1999-08-23 2006-02-02 Agoston Gregory E Methods of using 2-methoxyestradiol of high purity
US7087592B1 (en) * 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
US7235540B2 (en) * 1999-08-23 2007-06-26 Entremed, Inc. Methods of using 2-methoxyestradiol of high purity

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2742352A4 (en) * 2011-08-12 2015-05-13 Siemens Healthcare Diagnostics Detection of sex steroids

Also Published As

Publication number Publication date
JP5075626B2 (en) 2012-11-21
ECSP077228A (en) 2007-03-29
JP2008509109A (en) 2008-03-27
EP1776378B1 (en) 2009-11-04
IL180381A0 (en) 2007-06-03
ES2334244T3 (en) 2010-03-08
CA2573133A1 (en) 2006-02-09
BRPI0514096A (en) 2008-05-27
EP1776378A1 (en) 2007-04-25
MX2007001340A (en) 2007-03-27
US7910756B2 (en) 2011-03-22
WO2006013196A1 (en) 2006-02-09
ATE447580T1 (en) 2009-11-15
AU2005268768B2 (en) 2011-10-13
AU2005268768A1 (en) 2006-02-09
RU2007107914A (en) 2008-09-10
US20090012319A1 (en) 2009-01-08
CN1993376A (en) 2007-07-04
TW200611909A (en) 2006-04-16
CA2573133C (en) 2012-07-10
NO20070747L (en) 2007-04-23
AR050195A1 (en) 2006-10-04
DE602005017500D1 (en) 2009-12-17
KR20070040386A (en) 2007-04-16
ZA200700483B (en) 2008-09-25

Similar Documents

Publication Publication Date Title
US7910756B2 (en) Process for the preparation 2-substituted-derivatives of estrone and estradiol
FI83424C (en) FOERFARANDE FOER FRAMSTAELLNING AV NYA TERAPEUTISKT ANVAENDBARA SUBSTITUERADE ANDROSTA-1,4-DIEN-3,17-DIONER.
US20120214987A1 (en) Methods and compounds for preparing 3alpha-oxygen substituted steroids
US20180265540A1 (en) Synthesis of estetrol via estrone derived steroids
US4160027A (en) Steroid cyanoketones and intermediates
JP2677626B2 (en) 17-Substituted Androsta-1,4-dien-3-one Derivatives
IE55077B1 (en) Novel 19-thio-androstane derivatives
US4044004A (en) Total steroid synthesis employing substituted isoxazole derivatives
US3210388A (en) 13alpha-fluoro-17beta-methyl-18-nor steroids
JP2752366B2 (en) Process for the preparation of 17α-ethynyl-17β-hydroxy-18-methyl-4,15-estradien-3-one and intermediate products of this process
KR970005317B1 (en) Derivatives of 19-nor progesterone; process for producing them and the pharmaceutical compositions incorporating them
US3096350A (en) 6, 16alpha-dimethyl-delta1, 4, 6-pregnatriene-17alpha-ol-3, 20-dione and esters thereof
US3787394A (en) 19-nor-7alpha-methyl or 19-nor-20-spirox-4,14-dien-3-one and 18-methyl derivatives thereof
US3555096A (en) D-homogona-4,9-dienes and process
IE49235B1 (en) New derivatives of 2-substituted-19-nor steroids,processes for their preparation and pharmaceutical compositions containing them
Collins et al. 6α-and 6β-Acetic acid derivatives of Cholest-4-en-3-one and Pregn-4-ene-3, 20-dione
US3717663A (en) 9-alpha-methyl steroids
US3997574A (en) 9-α-methyl-steroids
IL32699A (en) 6-substituted-13-polycarbonalkyl-18,19 dinorpregn-4-en-3-ones,their preparation and pharmaceutical compositions containing them
US3458579A (en) D-homo-gona-4,9-dienes and process
US3686226A (en) 17-oxygenated-2-oxaestra-1(10),4-dien-3-ones and compounds corresponding
US3655652A (en) Aromatically-unsaturated 9alpha-methyl steroids
Gao et al. Synthetic Studies Toward 1a-Hydroxytestosterone from Testosterone
CA1125278A (en) Intermediate isoxazoles
Singh et al. Synthesis of calicoferol E

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION